drugset / Trial / NCT02817425

A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer

NCT02817425

Phase 2/3 Unknown 300 enrolled LanZhou University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to compare the three chemotherapy regimens(TEGAFOX Sequential S-1 or SOX Sequential S-1 or SOX non-Sequential S-1) for postoperative patients with gastric cancer, observe and record the efficacy and tolerance,to evaluate which regimen is better.

Timeline

Start
2013-05
Primary completion
2018-04
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 300 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg/m2 Oral
Subject S-1 Small molecule 40 mg Oral
Subject S-1 Small molecule 50 mg Oral
Subject S-1 Small molecule 60 mg Oral
Subject S-1 Small molecule 1000 mg/m2 Intravenous

Indications